Literature DB >> 27378451

Hyperparathyroidism complicating CYP 24A1 mutations.

Camille Loyer1, Clara Leroy2, Arnaud Molin3, Marie-Françoise Odou4, Damien Huglo5, Georges Lion6, Olivier Ernst7, Maxime Hoffmann8, Nicole Porchet9, Bruno Carnaille10, François Pattou11, Marie-Laure Kottler12, Marie-Christine Vantyghem13.   

Abstract

CYP24A1 gene mutations induce infantile hypercalcemia, with high 1,25(OH)2D contrasting with low PTH levels. The adult phenotype is not well known. Two unrelated adult patients were referred for nephrolithiasis, hypertension, hypercalcemia, hypercalciuria, normal 25-OHD levels, and inappropriate PTH levels (22 to 92pg/mL;N: 15-68) suggesting primary hyperparathyroidism, leading to surgery. Hypercalciuria improved despite persistent hypercalcemia, treated with cinacalcet. The ratio 25-OHD3/24-25-(OH)2D3>100 (N<25) suggested the diagnosis of CYP24A1 mutations which were confirmed through Sanger sequencing. In conclusion, the adult phenotype associated with CYP24A1 mutations can evolve over time from hypercalcemia with suppressed PTH towards hyperparathyroidism with moderately increased PTH level, adenoma and/or slightly increased parathyroid glands. Surgery decreased calciuria and improved kidney function. Cinacalcet was partially effective on hypercalcemia since PTH was inappropriate. This novel phenotype, a phenocopy of hyperparathyroidism, might evolve in few cases towards hyperparathyroidism despite random association of the 2 diseases cannot be excluded.
Copyright © 2016. Published by Elsevier Masson SAS.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27378451     DOI: 10.1016/j.ando.2016.03.002

Source DB:  PubMed          Journal:  Ann Endocrinol (Paris)        ISSN: 0003-4266            Impact factor:   2.478


  1 in total

Review 1.  Diseases associated with calcium-sensing receptor.

Authors:  C Vahe; K Benomar; S Espiard; L Coppin; A Jannin; M F Odou; M C Vantyghem
Journal:  Orphanet J Rare Dis       Date:  2017-01-25       Impact factor: 4.123

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.